eculizumab biosimilar(Isu Abxis)

依库珠单抗生物类似药（阿比克斯岛）

Report date: 2022/12/05 18:18:42

Base Information

Drug Nameeculizumab biosimilar(Isu Abxis)
Drug Alias Nameeculizumab biosimilarISU-305
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIsu Abxis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIsu Abxis Co Ltd
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalAtypical Hemolytic Uremic Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A